Page 2 - Cellmid Ltd News Today

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

Cellmid on track for profitability in FY2022 with planned revenue growth in ecommerce and new product launches The company has made progress in its new product development program with a hair loss supplement formulation completed and manufacturing and ecommerce set to launch during the first half of 2022. Cellmid is well-funded to implement its growth strategy after completing a $4.5 million capital raise in March, taking cash reserves to around $8.3 million after costs. Cellmid Lt...

Cellmid rights issue raises $3.81 million with strong support and plans follow-on placement for additional $700,000 Its lead manager and underwriter received bids from institutional and professional investors in excess of the available shortfall. Together with the follow-on placement, the company will raise a total of $4,516,369 before costs Cellmid Ltd’s (ASX:CDY) renounceable rights issue has raised $3,816,369, with strong support from existing shareholders and new institutional...

Proactive news headlines including Creso Pharma, Danakali, Golden Rim Resources and Brookside Energy April 01, 2021 02:21 ET | Source: Proactive Investors Proactive Investors London, UNITED KINGDOM Sydney, April 01, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Creso Pharma Ltd (ASX:CPH) (FRA:1X8) has utilised new technology to produc...

Search jobs 18-Jan-2021 Asia Pacific Alopecia Treatment Market Revenue to Worth Over US$ 3,214.8 Million by 2027, Owing to Increasing Clinical Trials in the Treatment of Alopecia Male or female pattern baldness, alopecia areata, telogen effluvium, and anagen effluvium are some of the types of alopecia. Topical alopecia drugs formulation are used in creams, oils, lotions, shampoos, foam forms that are intended to apply on the scalp in alopecia treatme...